Rita Nanda
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 132
- Cancer Immunotherapy and Biomarkers 47
- HER2/EGFR in Cancer Research 38
- Cancer Treatment and Pharmacology 27
- PARP inhibition in cancer therapy 19
-
- Advanced Breast Cancer Therapies 56
- Co-authors
- Olufunmilayo I. Olopade (34 shared papers)Charles M. Perou (8 shared papers)Maria Tretiakova (2 shared papers)Chad Livasy (1 shared paper)Gamze Karaca (1 shared paper)Dominic T. Moore (1 shared paper)Peter Schmid (12 shared papers)Dezheng Huo (25 shared papers)
- Journals
- Journal of Clinical Oncology (74 papers)Cancer Research (46 papers)Annals of Oncology (12 papers)Breast Cancer Research and Treatment (11 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Rita Nanda
193 papers receiving 6.5k citations
Rita Nanda's Hit Papers
Peers
Comparison fields: 5 of 117
- Oncology 3.7k
- Cancer Research 2.0k
- Immunology 955
- Pulmonary and Respiratory Medicine 1.2k
- Radiology, Nuclear Medicine and Imaging 552
Countries citing papers authored by Rita Nanda
This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).
Fields of papers citing papers by Rita Nanda
This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.
Co-authors
The 25 scholars most cited alongside Rita Nanda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 210 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Hit paper breakdown → | 2005 | 870 |
| 2 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 591 |
| 3 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 485 |
| 4 | Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 366 |
| 5 | 2009 | 298 | |
| 6 | 2005 | 202 | |
| 7 | 2013 | 198 | |
| 8 | 2013 | 171 | |
| 9 | 2021 | 163 | |
| 10 | 2008 | 163 | |
| 11 | 2017 | 161 | |
| 12 | 2013 | 158 | |
| 13 | 2019 | 149 | |
| 14 | 2005 | 149 | |
| 15 | 2017 | 140 | |
| 16 | 2015 | 119 | |
| 17 | 2019 | 116 | |
| 18 | 2017 | 96 | |
| 19 | 2015 | 93 | |
| 20 | Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database Hit paper breakdown → | 2023 | 91 |
About Rita Nanda
Rita Nanda is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 210 papers that have together received 6.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (56 papers), Cancer Immunotherapy and Biomarkers (47 papers), HER2/EGFR in Cancer Research (38 papers), Breast Cancer Treatment Studies (35 papers), Cancer Treatment and Pharmacology (27 papers), Cancer Genomics and Diagnostics (23 papers), PARP inhibition in cancer therapy (19 papers) and Radiopharmaceutical Chemistry and Applications (14 papers). The work is most often cited by research in Oncology (3.7k citations), Cancer Research (2.0k citations), Immunology (955 citations), Pulmonary and Respiratory Medicine (1.2k citations) and Radiology, Nuclear Medicine and Imaging (552 citations). Rita Nanda has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Olufunmilayo I. Olopade, Charles M. Perou, Maria Tretiakova, Chad Livasy, Gamze Karaca, Dominic T. Moore, Peter Schmid, Dezheng Huo, Tatyana A. Grushko and Eric P. Winer. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.